がん患者に対するヨガ介入に関するランダム化比較試験の計量書誌学的解析:10年間のレビュー

Selvaraj Giridharan1, Nagaraj V Kumar2

  • 1Oncology Department, Tawam Hospital, Al Ain, ARE.

Cureus
|May 27, 2024
PubMed

本文献レビューでは、がん患者に対する補完療法としてのヨガの潜在的な有用性について、2014年から2023年の間に実施されたランダム化比較試験のビブリオメトリック分析を提示する。本分析を行うため、Scopus、Cochrane、PubMedなどの医学および科学データベースを、関連するキーワードを用いて検索した。検索の結果、4,762名の患者が参加した58件の臨床試験が抽出され、この研究分野における増加傾向が示された。レビューした研究は主に乳がん患者に焦点を当てたものであり、ヨガの適応性と汎用性が実証され、希望と楽観的な展望が示された。さまざまなヨガのスタイルのうち、これらの臨床試験で最も頻繁に実践されていたのはハタヨガであった。本分析により、ヨガによる介入はがんケアにおいて有望な役割を果たし、がん患者にとって価値のある補完療法となり得ることが明らかになった。しかし、この研究領域には依然として対処すべき重要な空白や限界が存在する。例えば、がん患者に対するヨガ介入の潜在的な有用性をさらに確立するためには、より厳格で多様な調査が必要である。加えて、治療効果を最適化するためには、ヨガ介入の標準化が不可欠である。これらの空白や限界に対処することで、がん患者に対する補完療法としてのヨガの可能性をさらに高めることができる。

関連する概念動画

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
343
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K